Tag: events

Oslo, Norway (15 August 2025) – TGS has issued awards of Performance Share Units (PSUs) and Restricted Share Units (RSUs) to 283 key employees of the Company, as authorized by the shareholders of the company at its Annual General Meeting on 8 May 2025.  With the exception of certain PSUs and RSUs, which may be secured by the Company’s treasury stock, the PSUs and RSUs are secured by free-standing warrants that, upon vesting of the PSUs and RSUs in accordance with their terms, are convertible to shares of the Company’s common stock.  Each PSU represents the right to receive a maximum of 1.5 shares, while each RSU represents the right to receive one share.

OTTAWA, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the 2025 Newfoundland & Labrador Wildfires Appeal to help people and communities impacted by fires in the province.

Accelerating cleantech economic growth and sustainability initiatives through innovation, collaboration and education

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Fly-E Group, Inc. (Nasdaq: FLYE) (“Fly-E” or the “Company”), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters, today announced the grand opening of its newest retail location in Boston, Massachusetts. The new store, now fully operational, marks the Company’s continued expansion in the Northeastern United States and underscores its mission to make safe, reliable, and eco-friendly transportation accessible to more communities.

Landmark listing makes Kyivstar the first and only publicly listed pure-play Ukrainian investment opportunity in the U.S. Stock Markets

CINCINNATI, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reported financial results for the second quarter ended June 30, 2025.

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Joins Workhorse’s proven vehicles, manufacturing capabilities and national dealer network with Motiv’s diverse product portfolio and top fleet relationships

Shrisha Radhakrishna appointed as President and interim leader of Opendoor

Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85